BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TRU-016: Phase Ib/II started

Emergent began an open-label, U.S. Phase Ib/II trial of TRU-016 in combination with rituximab and bendamustine in 88 patients who failed prior treatments. The Phase Ib portion will evaluate 10 and 20 mg/kg IV TRU-016 on days 1 and 15 of a 28-day cycle in combination with rituximab and bendamustine in up to 12 patients. The Phase II portion will compare the dose selected in the first portion plus rituximab and bendamustine vs....

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >